What is Merck & Co. (MSD) and CEPI collaborating on?

They are partnering on a $30 million program to develop an updated, more affordable version of Merck's Ebola vaccine, Ervebo.

How will the new Ebola vaccine be improved?

The updated vaccine will aim to improve manufacturing yield, extend shelf life, and reduce overall production costs.

Who will benefit from the updated Ebola vaccine?

The initiative specifically targets improving access and affordability for low- and middle-income countries.

Home / Health / Merck & CEPI Partner for Cheaper Ebola Vaccine

Merck & CEPI Partner for Cheaper Ebola Vaccine

23 Jan

•

Summary

Partnership aims to create a more affordable Ebola vaccine version.
Updated vaccine will improve manufacturing yield and extend shelf life.
Goal is to enhance access for low- and middle-income countries.

Merck & CEPI Partner for Cheaper Ebola Vaccine

A significant collaboration has been announced between Merck & Co.'s unit, MSD, and the Coalition for Epidemic Preparedness Innovations (CEPI). This partnership, backed by $30 million, is focused on enhancing the accessibility and affordability of Merck's Ebola vaccine, Ervebo.

The initiative will concentrate on optimizing Ervebo's manufacturing process. The aim is to boost production yields and extend the vaccine's shelf life, making it easier and less costly to produce on a larger scale.

Improvements are expected to allow the vaccine to be stored in standard refrigerators for extended periods. MSD will work with Hilleman Laboratories, while SK bioscience and IDT Biologika will handle the drug substance and product development, respectively.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.